Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
Lorey K Smith, Tiffany Parmenter, Cathryn M Gould, Piyush B Madhamshettiwar, Karen E Sheppard, Kaylene J Simpson, Grant A McArthur
Scientific Data | NATURE RESEARCH | Published : 2020
Identification of mechanisms underlying sensitivity and response to targeted therapies, such as the BRAF inhibitor vemurafenib, is critical in order to improve efficacy of these therapies in the clinic and delay onset of resistance. Glycolysis has emerged as a key feature of the BRAF inhibitor response in melanoma cells, and importantly, the metabolic response to vemurafenib in melanoma patients can predict patient outcome. Here, we present a multiparameter genome-wide siRNA screening dataset of genes that when depleted improve the viability and glycolytic response to vemurafenib in BRAFV600 mutated melanoma cells. These datasets are suitable for analysis of genes involved in cell viability ..View full abstract
Related Projects (2)
Awarded by National Health and Medical Research Council of Australia
We thank Daniel Thomas, Jennii Luu, and Yanny Handoko from the Victorian Centre for Functional Genomics core facility (Peter MacCallum Cancer Centre) for technical assistance with the primary and secondary siRNA screens. The VCFG (K.J.S.) is funded by the Australian Cancer Research Foundation (ACRF), the Australian Phenomics Network (APN) through funding from the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS) program and the Peter MacCallum Cancer Centre Foundation. This work was supported by the Peter MacCallum Cancer Centre Foundation and grants from National Health and Medical Research Council of Australia (#1053792 and #1106576).